Anaesthetists have a higher incidence of substance use disorder when compared with other doctors. This might be due to the ease of access to intravenous opioids, propofol, midazolam, inhalational agents and other anaesthetic drugs. Alcohol use disorder continues to be the most common problem. Unfortunately, the first sign that something is amiss might be the anaesthetist's death from an accidental or deliberate overdose. While there are few accurate data, suicide is presumed to be the cause of death in approximately 6-10% of all anaesthetists. If we are to prevent this, substance use disorder must be recognised early, we should ensure the anaesthetist is supported by their department and hospital management and that the anaesthetist engages fully with treatment. Over 75% of anaesthetists return to full practice if they co-operate fully with the required treatment and supervision.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/anae.15732 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Psychedelic Treatments in Adolescent Psychopharmacology: Considering Safety, Ethics, and Scientific Rigor.
J Child Adolesc Psychopharmacol
January 2025
Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Interest in psychedelic therapies for adults is rapidly growing, with substances like 3,4-methylenedioxymethamphetamine for posttraumatic stress disorder, psilocybin for treatment-resistant depression, and lysergic acid diethylamide for generalized anxiety disorder showing promise. However, research on these therapies in children and adolescents is limited, with no recent trials. Despite this lack of scientific exploration, adolescents may still experiment with these substances for both recreational and therapeutic purposes as accessibility continues to increase.
View Article and Find Full Text PDFTrends in Treatment Need and Receipt for Substance Use Disorders in the US.
JAMA Netw Open
January 2025
Institute of Therapeutic Innovations and Outcomes, College of Pharmacy, The Ohio State University, Columbus.
Long-Acting Injectable Antipsychotics in Adolescents with Bipolar Disorder.
J Child Adolesc Psychopharmacol
January 2025
Director of Co-Founder and Founder of Schizophrenia Society, University of Cincinnati, Cincinnati, Ohio, USA.
Bipolar disorder often begins in adolescence or early adulthood, characterized by recurrent manic episodes that can lead to neurodegenerative brain changes and functional decline. While several oral second-generation antipsychotics are Food and Drug Administration (FDA)-approved for mania, adherence to maintenance treatment is frequently poor due to factors such as anosognosia, cognitive dysfunction, impulsivity, side effects aversion, and substance use. Long-acting injectable (LAI) antipsychotics, approved for adults with bipolar mania or schizoaffective disorder (bipolar type), offer a potential solution for adolescents with similar conditions.
View Article and Find Full Text PDFEfficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel.
Neurol Ther
January 2025
Department of Psychiatry, Faculty of Medicine, Mental Health Unit, Virgen del Rocio University Hospital, Translational Psychiatry Group, IBiS-CSIC, CIBERSAM, University of Seville, Seville, Spain.
Introduction: For patients with psychosis, early, intensive therapeutic intervention is thought to improve long-term outcomes. Furthermore, patients with a first-episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the longer term if they continue low-dose antipsychotic treatment. Lurasidone is an atypical antipsychotic agent which is approved in Europe for the treatment of schizophrenia in adults and adolescents (13-17 years).
View Article and Find Full Text PDFImpact of Positive Childhood Experiences (PCEs): A Systematic Review of Longitudinal Studies.
Child Psychiatry Hum Dev
January 2025
Child Health Research Centre, The University of Queensland, South Brisbane, QLD, 4101, Australia.
Positive Childhood Experiences (PCEs) may mitigate the negative outcomes resulting from Adverse Childhood Experiences (ACEs). To date, most PCE research has used cross-sectional or retrospective designs. PubMed, EMBASE, Cochrane, PsychINFO, CINAHL, and Scopus were searched in May 2024 for longitudinal studies that examined the impact of cumulative PCEs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!